Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05836220
Other study ID # PP3003
Secondary ID 2023-504339-41
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 15, 2023
Est. completion date May 2025

Study information

Verified date May 2024
Source Pathalys Pharma
Contact Pathalys Clinical Trials
Phone Please reach out by email
Email clinicaltrials@pathalys.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they will receive dose-titrated PLS240 for an additional 26 weeks. Throughout the duration of the study, patients will be expected to attend multiple study visits where an investigator will collect blood, preform electrocardiograms (ECGs) and physical exams, and further assess the safety and efficacy of PLS240.


Recruitment information / eligibility

Status Recruiting
Enrollment 375
Est. completion date May 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Aged 18 - 80 years at time of informed consent. 2. Prescribed hemodialysis for 3 times per week and on therapy for at least 3 months and has a delivered Kt/V=1.2 within 4 weeks prior to signing the ICF. 3. Pre-dialysis central laboratory iPTH must be =400 pg/mL on at least two assessments performed at 2 visits, at least 1 week apart during the Active Screening period. iPTH may be tested up to 4 times. at least performed at least a week after the previous iPTH. 4. Pre-dialysis central laboratory cCa must be =8.3 mg/dL on at least one assessment performed during the Active Screening period. cCa may be tested up to 3 times during the Active Screening period. 5. Dialysate calcium concentration =2.5 mEq/L (1.25 mmol/L) and stable for at least 4 weeks prior to signing the ICF. 6. Participants receiving active Vitamin D sterols (e.g., doxercalciferol or calcitriol) to manage SHPT must be on a stable dose (e.g., maximum dose change =50%), in the opinion of the investigator or sub-investigator, within the 2 months prior to signing the ICF, remain stable, as defined as no increase in dose, through the screening period, and be expected to maintain a stable dose, as defined as no increase in dose, for the duration of the study. 7. Participants receiving phosphate binders must be on a stable dose (e.g., maximum dose change =50%), in the opinion of the investigator or sub-investigator, within the 2 months prior to signing the ICF, remain stable through the screening period, and be expected to maintain stable dose for the duration of the study. 8. Participants receiving calcium supplements must be on a stable dose (e.g., maximum dose change =50%), in the opinion of the investigator or sub-investigator, within the 2 months prior to signing the ICF and remain stable through the screening period. 9. Female participants who are post-menopausal ('post-menopausal' women have had no menses for the previous year and are over the age of 50 years), or surgically sterilized, or have a medical condition that prevents pregnancy, or commit to remain abstinent during the study and for 2 weeks after the last dose of the investigational product (IP), or are willing to use highly effective contraception during the study and for 2 weeks after the last dose of IP. Women of child-bearing potential must have a negative serum pregnancy test during the screening period. 10. Male participants who are willing to use highly effective contraception when sexually active and will not donate sperm during the treatment phase and for 2 weeks after the last dose of IP. 11. Voluntarily given written informed consent to participate in this study. 12. Agrees to not participate in another study of an investigational agent during the study To be eligible for inclusion into the Open-Label Extension Phase of the study, participants must fulfill the additional following criteria at the time of entry into the Open-Label Extension Phase: 13. Have successfully completed the course of treatment and final safety follow-up visit of the Double-Blind Phase. 14. Voluntarily given written informed consent to participate in the Open-Label Extension Phase of the study. 15. Prescribed hemodialysis for 3 times per week. 16. Continue to meet Inclusion Criteria 9, 10, and 12. Exclusion Criteria: 1. Diagnosis of primary hyperparathyroidism. 2. Pre-dialysis central laboratory Active Screening iPTH >1500 pg/mL on two or more occasions. iPTH may be tested up to 4 times during the Active Screening period. 3. History of parathyroid intervention including parathyroidectomy (PTx) and percutaneous ethanol injection therapy (PEIT) within 26 weeks before signing the ICF. 4. Treatment with any prohibited medication as defined in Section 8.3.1. 5. Anticipated or scheduled parathyroidectomy during the study period. 6. Planned living-related or living-unrelated kidney transplant during the study period. 7. Change in mode of dialysis (e.g., from hemodialysis to hemodiafiltration, peritoneal dialysis to hemodialysis, at home to in center dialysis), dialysate Ca concentration, or prescribed dialysis treatment time within 4 weeks before signing the ICF. 8. Noncompliant with hemodialysis (i.e., missing more than 2 dialysis sessions within 8 weeks prior to signing the ICF, unless absence is due to hospitalization or dialysis-access procedures). 9. Clinically significant abnormalities on screening laboratory tests (may repeat abnormal laboratory tests) according to the Investigator including but not limited to the following: 1. Serum albumin =3.0 g/dL 2. Serum magnesium <1.5 mg/dL 3. Serum P >8.0 mg/dL 4. Hemoglobin <8.5 g/dL 5. Platelet count <100,000 x106/L 6. Serum transaminase (alanine transaminase [ALT] or serum glutamic pyruvic transaminase [SGPT], alanine transaminase [AST] or serum glutamic oxaloacetic transaminase [SGOT]) =2.5 times the upper limit of normal (ULN) during Active Screening. 10. Diagnosed with an unstable medical condition, defined as having been hospitalized, other than for dialysis vascular access intervention, within 30 days prior to signing the TCF, or otherwise unstable in the judgment of the investigator. 11. History of malignancy within the last 2 years prior to signing the ICF (except squamous or basal cell skin cancers, or cervical carcinoma in situ). 12. Recent history (within 4 weeks prior to signing the ICF) of angina pectoris with symptoms that occur at rest or minimal activity. Chest pain on dialysis (within 8 weeks prior to signing the ICF) unless evaluated by a cardiologist with documentation that the chest pain is not due to cardiac ischemia. 13. History of New York Heart Association (NYHA) Functional Class 3 or 4 heart failure. 14. History of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 4 months prior to signing the ICF. 15. Stroke (cerebral infarction or cerebral hemorrhage) within 6 months prior to signing the ICF. 16. Participant is receiving treatment for a seizure disorder or has a history of a seizure within 12 weeks prior to signing the ICF. 17. Poorly controlled diabetes mellitus, in the judgment of the investigator or sub-investigator. 18. Poorly controlled hypertension (defined as post-dialysis [seated if available] systolic pressure >180 mmHg or diastolic pressure >110 mmHg) at 2 or more dialysis sessions during the 2 weeks prior to signing the ICF. 19. Enrolled in other invasive investigational device or investigational drug trials, within at least 30 days prior to signing the ICF or are receiving other investigational agents (experimental dialysis machines are acceptable). 20. History of symptomatic ventricular dysrhythmias or Torsade de Pointes. 21. History of or family history of long QT syndrome. 22. QTcF >500 msec on screening ECG. 23. Pregnant or breast feeding. 24. Prior exposure or hypersensitivity to PLS240 or any of its components. 25. Current, recent, or suspected infection with SARS-CoV-2/COVID-19 within 4 weeks prior to signing the ICF. 26. In the opinion of the investigator, any disorder that would interfere with understanding and giving informed consent, or compliance with protocol requirements. Participants must be excluded from the Open-Label Extension Phase of the study, in case of the following at the time of entry into the Open-Label Extension Phase: 27. In the opinion of the investigator, continuation into the Open-Label Extension Phase is not considered safe and/or feasible. 28. Continues to meet Exclusion Criterion #5. 29. iPTH >1500 pg/mL at the final assessment during the EAP and at the Follow-up visit of the Double-Blind Phase.

Study Design


Intervention

Drug:
PLS240
Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
Placebo
Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
Open-Label Extension PLS240
Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.

Locations

Country Name City State
Bulgaria Site Number: BGR001-2 Gabrovo
Bulgaria Site Number: BGR003-2 Lom Montana
Bulgaria Site Number: BGR002-2 Ruse
Bulgaria Site Number: BGR004-2 Varna
Poland Site Number: POL001-2 Lódz Lódzkie
Poland Site Number: POL004-2 Olkusz Malopolskie
Poland Site Number: POL002-2 Poznan Wielkopolskie
Poland Site Number: POL003-2 Pszczyna Slaskie
Poland Site Number: POL005-2 Warszawa Mazowieckie
Portugal Site Number: PRT001-2 Carnaxide
Portugal Site Number: PRT002-2 Covilhã Castelo Branco
Portugal Site Number: PRT003-2 Lisboa
Serbia Site Number: SRB003-2 Belgrade
Serbia Site Number: SRB005-2 Beograd Belgrade
Serbia Site Number: SRB001-2 Kruševac
Serbia Site Number: SRB002-2 Niš
Serbia Site Number: SRB004-2 Užice
Spain Site Number: ESP003-2 Córdoba Cordoba
Spain Site Number: ESP005-2 Manises Valencia
United States Site Number: USA007-2 Amherst New York
United States Site Number: USA039-2 Anaheim California
United States Site Number: USA023-2 Arvada Colorado
United States Site Number: USA031-2 Aurora Colorado
United States Site Number: USA041-2 Boca Raton Florida
United States Site Number: USA053-2 Charlotte North Carolina
United States Site Number: USA001-2 Chula Vista California
United States Site Number: USA013-2 Columbus Georgia
United States Site Number: USA026-2 Durham North Carolina
United States Site Number: USA003-2 El Centro California
United States Site Number: USA011-2 El Paso Texas
United States Site Number: USA020-2 Escondido California
United States Site Number: USA051-2 Fairfax Virginia
United States Site Number: USA004-2 Fort Myers Florida
United States Site Number: USA042-2 Fresno California
United States Site Number: USA034-2 Fullerton California
United States Site Number: USA046-2 Glendale California
United States Site Number: USA019-2 Granada Hills California
United States Site Number: USA055-2 Greenville Texas
United States Site Number: USA002-2 Hollywood Florida
United States Site Number: USA025-2 Kalamazoo Michigan
United States Site Number: USA027-2 Knoxville Tennessee
United States Site Number: USA005-2 La Mesa California
United States Site Number: USA044-2 Lancaster California
United States Site Number: USA029-2 Live Oak Texas
United States Site Number: USA030-2 Los Angeles California
United States Site Number: USA043-2 Los Angeles California
United States Site Number: USA017-2 Middlebury Connecticut
United States Site Number: USA016-2 Minneapolis Minnesota
United States Site Number: USA028-2 Mishawaka Indiana
United States Site Number: USA022-2 Moorpark California
United States Site Number: USA054-2 New Orleans Louisiana
United States Site Number: USA015-2 Newark Delaware
United States Site Number: USA033-2 Northridge California
United States Site Number: USA049-2 Northridge California
United States Site Number: USA045-2 Roseburg Oregon
United States Site Number: USA048-2 Roseville Michigan
United States Site Number: USA038-2 Saint George Utah
United States Site Number: USA008-2 San Antonio Texas
United States Site Number: USA012-2 San Antonio Texas
United States Site Number: USA018-2 San Dimas California
United States Site Number: USA035-2 South Miami Florida
United States Site Number: USA010-2 Spartanburg South Carolina
United States Site Number: USA021-2 Tarzana California
United States Site Number: USA056-2 Tarzana California
United States Site Number: USA009-2 Toledo Ohio
United States Site Number: USA052-2 Victorville California
United States Site Number: USA037-2 Virginia Beach Virginia
United States Site Number: USA006-2 Waxahachie Texas
United States Site Number: USA024-2 Wichita Kansas

Sponsors (2)

Lead Sponsor Collaborator
Pathalys Pharma Launch Therapeutics

Countries where clinical trial is conducted

United States,  Bulgaria,  Poland,  Portugal,  Serbia,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of PLS240 treated participants compared to the portion of placebo treated participants with a =30% decrease in mean iPTH Double-Blind Phase only. This measurement will be calculated based on the Efficacy Assessment Period (Weeks 22 - 27) relative to the mean baseline iPTH (all Active Screening and predose Day 1 iPTH values). each visit from screening through week 27
Primary Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <7.5 mg/dL up to week 28
Primary Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <8.3 mg/dL up to week 28
Primary Open-Label Phase: Number of AE's up to week 28
Primary Open-Label Phase: Number of SAE's up to week 28
See also
  Status Clinical Trial Phase
Completed NCT02549417 - Phase 3 Study of KHK7580 Phase 3
Completed NCT02549404 - Phase 3 Study of KHK7580 Phase 3
Not yet recruiting NCT02536287 - Comparison of Total Parathyroidectomy With and Without Autotransplantation Phase 3
Completed NCT02549391 - Phase 3 Study of KHK7580 Phase 2/Phase 3
Active, not recruiting NCT03023748 - Intravenous Paricalcitol in Chronic Hemodialysis Patients Phase 4
Withdrawn NCT01426724 - Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease N/A
Completed NCT01101113 - Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Phase 4
Completed NCT01220050 - Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism Phase 2
Completed NCT00537979 - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Phase 4
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT00431496 - A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Phase 4
Completed NCT00117052 - SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism Phase 3
Completed NCT00073710 - Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Phase 4
Completed NCT03626948 - SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis Phase 3
Completed NCT01382212 - A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis Phase 3
Completed NCT01219855 - Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) Phase 2/Phase 3
Completed NCT01224782 - Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) N/A
Completed NCT00999037 - FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease N/A
Completed NCT00990704 - Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism Phase 2
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2